Traumatization of neurospheres for elicitation of tau aggregation in their constituent neurons

损伤神经球以引发其组成神经元中的 tau 蛋白聚集

• 批准号: 492049-2015
• 负责人: Yadav, VikramadityaGanapati
• 金额: $ 1.82万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=587175
• 关键词: Traumatization; neurospheres; elicitation; tau; aggregation

The treatment of neurodegenerative diseases such as Alzheimer's disease (AD), chronic traumatic encephalopathy (CTE) and frontotemporal dementia (FTD) is an urgent national priority. However, there are no known therapies against these diseases. Drug discovery in this category has been stymied by the absence of reliable screening tools for evaluating the performance of drug candidates before they are tested on human patients in clinical trials. Specifically, the model systems employed by the pharmaceutical industry to screen drug candidates do not accurately recapitulate the microenvironment of a degenerated human brain. To this end, our research group at the University of British Columbia, in collaboration with scientists from STEMCELL Technologies Inc., proposes to apply principles and methodologies of tissue engineering to construct a faithful and accurate mimic a degenerated human brain for use as a drug screening platform. Specifically, the current proposal seeks to develop and validate a key step in the construction of the model organ - the elicitation of neurodegeneration in otherwise healthy brain tissue, and we will employ recent insights about biochemical similarities and dissimilarities between AD, CTE and FTD to achieve our goal. We anticipate that the current project will lay the foundations for the eventual development of an organoid biomanufacturing platform that will be integrated into the pharmaceutical industry's existing drug discovery infrastructure.

阿尔茨海默病（AD）、慢性创伤性脑病（CTE）和额颞叶痴呆（FTD）等神经退行性疾病的治疗是一项紧迫的国家优先事项。然而，没有已知的针对这些疾病的疗法。由于缺乏可靠的筛选工具来评估候选药物在临床试验中对人类患者进行测试之前的性能，这类药物的发现一直受到阻碍。具体来说，制药行业用来筛选候选药物的模型系统并不能准确地概括退化人脑的微环境。为此，我们在不列颠哥伦比亚省大学的研究小组与STEMCELL Technologies Inc.的科学家合作，提出应用组织工程学的原理和方法，构建一个忠实准确的退化人脑模拟物，作为药物筛选平台。具体来说，目前的提案旨在开发和验证模型器官构建中的关键步骤-在其他健康脑组织中引发神经退行性变，我们将采用最近关于AD，CTE和FTD之间生物化学相似性和差异性的见解来实现我们的目标。我们预计，目前的项目将为最终开发一个类器官生物制造平台奠定基础，该平台将整合到制药行业现有的药物发现基础设施中。